TRD, or treatment-resistant depression, is a type of depression that does not respond well to traditional forms of treatment, such as medication and therapy. It can be caused by a variety of factors, including genetic predisposition, brain chemistry, and life experiences. Spravato is a new FDA-approved treatment for TRD that has been shown to be effective in reducing the symptoms of depression. In this article, we will discuss Spravato for TRD, causes of TRD and how Spravato can help.

TRD is often caused by a combination of factors. For instance, someone who has a family history of depression may be more likely to experience TRD than someone without a family history of the condition. Additionally, people who have experienced traumatic events in their lives, such as abuse or neglect, are also more likely to develop TRD. Finally, brain chemistry can play a role in the development of TRD. Imbalances in neurotransmitters, such as serotonin and norepinephrine, have been linked to the condition.

Morever, there are several key statistics about TRD that are important to know. Females are more likely to experience both MDD and TRD at a rate of 2.6 times that of males. In addition, people with TRD often have a comorbidity, meaning they experience another mental illness alongside their depression, such as anxiety or bipolar disorder (30% of bipolar patients experience TRD during depressive phases). In addition, the average cost for a single TRD episode is $5,000-$10,000, making it a significant financial burden for many individuals and families. 30% of people diagnosed with depression suffer from treatment-resistant depression, and 37% of those resist strategies meant to help them.

Spravato is a new FDA-approved treatment for TRD that has been shown to be effective in reducing the symptoms of depression. Spravato is a nasal spray that delivers esketamine, a chemical cousin of ketamine, into the bloodstream. Esketamine has been shown to block the reuptake of glutamate, which is thought to play a role in the development of depression. In clinical trials, Spravato has been shown to reduce the symptoms of depression within two days, and the effects can last up to four weeks.

There are several preconditions that must be met before a patient can be prescribed Spravato. First, the patient must be 18 years of age or older. Second, the patient must be diagnosed with TRD by a psychiatrist. Third, the patient must have tried at least two other antidepressants that have failed to provide relief. Finally, the patient must be enrolled in a Spravato treatment program that includes regular psychiatric monitoring.

If you or someone you know is struggling with TRD, Spravato may be a viable treatment option. At PsyFi TMS, we are proud to offer Spravato as an option for our patients. To learn more about Spravato, please contact us at info@psyfitms.com. We also offer Transcranial Magnetic Stimulation (TMS), which is another FDA-approved treatment for depression. TMS uses magnetic pulses to stimulate the brain and has been shown to be effective in treating both TRD and MDD.